News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Abcam plc (ABC.L) And Cell Marque Sign Global Strategic Marketing Agreement For IVD IHC RabMAb Antibodies

9/4/2014 9:42:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cambridge, UK, September 4, 2014: Abcam plc, a global leader in the manufacture and supply of innovative protein research tools and services, and Cell Marque Corporation, a provider of antibodies and reagents for diagnostic immunohistochemistry, announced today they have signed a global 10-year strategic marketing agreement for Abcam’s in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb® primary antibody portfolio.

Under the agreement, Cell Marque will apply its extensive IVD expertise to incorporate Abcam’s IVD IHC RabMAb primary antibodies into its portfolio and use its established distribution channels to distribute them to the global market. The agreement will give customers faster, easier access to Abcam’s high-quality antibodies.

The antibodies use Abcam’s powerful RabMAb technology offering superior binding affinity and specificity, and have been specifically developed to provide high-quality results to pathology laboratories for immunohistochemical staining of formalin-fixed paraffin embedded (FFPE) tissue.

Alan Hirzel, Chief Marketing Officer, Abcam, commented: “We are excited about the growth opportunity that this agreement provides. Part of our strategy is to work with partners that offer complementary high-quality products and who share our vision of enabling researchers to discover more. The agreement with Cell Marque will enable Abcam to extend its reach within the in vitro diagnostics market, with a broader range of customers able to access our in-house developed RabMAb products.”

Nora Lacey, President and CEO of Cell Marque, commented: “The addition of Abcam’s IVD RabMAb products complements our current portfolio. The agreement with Abcam demonstrates Cell Marque’s ability to meet the quality and performance requirements of pathologists and will expand our offering of exceptional quality diagnostic tools.”

To find out more, please visit and

Notes to editors
Francesca Axe
T: +44 (0) 1223 696000

Media enquiries
Katie Odgaard
Zyme Communications
T: +44 (0) 7787 502 947

About Abcam
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support and next-day delivery to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam was admitted to AIM in 2005 (AIM: ABC). To find out more, please visit

About Cell Marque

Headquartered in Rocklin, CA, Cell Marque Corporation is a worldwide leader in developing, manufacturing and marketing quality and innovative antibodies for diagnostic and research use in immunohistochemistry. Cell Marque products are critical tools used in cancer diagnosis and helping improve patients’ lives.

For more information, please visit

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus
Abcam plc